[HTML][HTML] Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: A randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu… - Oncotarget, 2015 - scholar.nycu.edu.tw
Objective: To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
[引用][C] Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - cir.nii.ac.jp
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a
randomized, open-label, prospective trial | CiNii Research CiNii 国立情報学研究所 学術情報 …
randomized, open-label, prospective trial | CiNii Research CiNii 国立情報学研究所 学術情報 …
[HTML][HTML] Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - oncotarget.com
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a
randomized, open-label, prospective trial | Oncotarget Online ISSN: 1949-2553 Search …
randomized, open-label, prospective trial | Oncotarget Online ISSN: 1949-2553 Search …
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - europepmc.org
Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - europepmc.org
Objective To analyze the efficacy of gemcitabine with or without erlotinib for pancreatic
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
cancer, and to determine the predictive role of epidermal growth factor receptor (EGFR) and …
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
JP Wang, CY Wu, YC Yeh, YM Shyr, YY Wu, CY Kuo… - Oncotarget, 2015 - oncotarget.com
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a
randomized, open-label, prospective trial | Oncotarget Online ISSN: 1949-2553 Search …
randomized, open-label, prospective trial | Oncotarget Online ISSN: 1949-2553 Search …